Skip to content

Press

Portfolio-Media Coverage
Gene Editing Therapies Delivered In Vivo: Ensoma’s Emile Nuwaysir on The Long Run
April 24, 2023 Apr 24, 2023 The Timmerman Report
Portfolio-Media Coverage
Nido Biosciences divulges new SARMs
February 10, 2023 Feb 10, 2023 Bioworld
Portfolio-Media Coverage
Ensoma Raises $85M in Series B Funding; Acquires Twelve Bio
January 10, 2023 Jan 10, 2023 FinSMEs
Portfolio-Media Coverage
Ensoma announces financing and acquisition
January 9, 2023 Jan 9, 2023 The Pharma Letter
Portfolio-Media Coverage
Ensoma buys a startup to advance ‘in vivo’ cell therapy work
January 6, 2023 Jan 6, 2023 Biopharma Dive
Portfolio-Media Coverage
Ensoma acquiring Twelve Bio
January 6, 2023 Jan 6, 2023 Labiotech
Portfolio-Media Coverage
On in vivo cell therapy quest, Takeda-backed Ensoma buys a CRISPR upstart and bags $85M
January 5, 2023 Jan 5, 2023 Endpoints
Portfolio-Media Coverage
Portfolio company Twelve Bio to be acquired alongside $85 million financing of Ensoma
January 5, 2023 Jan 5, 2023 Bloomberg
Portfolio-Media Coverage
Can “Gene Writing” Deliver What Gene Editing Can’t?
December 12, 2022 Dec 12, 2022 The Scientist
Portfolio-Media Coverage
Harvard spinout Surge emerges with $26M to make immunotherapy part of cancer surgery
October 21, 2022 Oct 21, 2022 MedCity News